“Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025051. doi:10.4084/MJHID.2025.051.